Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

manilatimes.net · 2026-09-16

CONSHOHOCKEN, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on September 1, 2026 and September 14, 2026 to a total of 27 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

TickrTrends take: Madrigal Pharmaceuticals announced inducement awards to employees under Nasdaq rules, which typically reflects ongoing recruitment and retention efforts as the company expands operations. TickrTrends is currently awaiting full valuation analysis for MDGL, meaning key financial metrics and competitive positioning within the Healthcare sector are still being assessed. Investors focused on valuation should monitor how such employee incentives affect the company's future expense structure and cash runway as these factors will inform any eventual valuation determination.

Read the full story at manilatimes.net →